Biologics Center "Device Action Plan" Omits Specific Review Times
This article was originally published in The Gray Sheet
The FDA Center for Biologics and Research's "Device Action Plan" released April 27 lacks specific review times, making it hard for device manufacturers to evaluate and anticipate the center's review performance, industry reps maintain.
You may also be interested in...
FDA's Center for Biologics Evaluation and Research should adopt the Center for Device and Radiological Health's warning letter pilot program for non-blood related devices, Gen-Probe Senior Director of Regulatory Affairs Glen Freiberg told an Oct. 6 session of the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.